Navigation Links
Prismic Pharmaceuticals Acquires Scarista's Exclusive License to Amarin's Omega-3 Patents for CNS Disorders
Date:2/7/2012

SCOTTSDALE, Ariz., Feb. 7, 2012 /PRNewswire/ -- Prismic Pharmaceuticals, Inc., a Scottsdale, Arizona-based, emerging pharmaceutical company, today announced that it has completed the acquisition of the assets of Scarista Limited. In particular, Prismic has acquired Scarista's exclusive license from Amarin Neuroscience Limited, a wholly owned subsidiary of Amarin Corporation, to develop, market, and out-license products based on a portfolio of issued U.S. and foreign composition and use patents covering highly purified forms of Omega-3 fatty acids alone or in combination with other molecules for the treatment of disorders of the central nervous system (CNS). 

Commenting on this acquisition, Peter Moriarty, the Chairman and co-founder of the company, stated, "This is an important milestone in the development of Prismic Pharmaceuticals. Having gained access to the robust patents through the acquisition of Scarista, Prismic is planning to partner with one or more pharmaceutical companies in order to maximize the considerable commercial opportunity the patents offer in the CNS area."  

"There is already an established body of research and clinical experience indicating the therapeutic benefits and safety of highly purified forms of EPA and DHA for the treatment of cardiovascular disease. There is also similar data relating to their use in the treatment of a number of CNS disorders," Moriarty added. "Prismic, therefore, believes that any company licensing our IP will have the opportunity to bring patent-protected formulations to market relatively expeditiously." 

About Prismic Pharmaceuticals, Inc.

Prismic Pharmaceuticals, Inc., is a privately held pharmaceutical company focused on the development and marketing of novel prescription pharmaceuticals for psychiatric and neurodegenerative disorders, and prescription medical foods for the clinical dietary management of the metabolic processes associate
'/>"/>

SOURCE Prismic Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)...  Ardelyx, Inc. (NASDAQ: ARDX ), a clinical-stage ... today announced that the Company will host its inaugural ... 1:00 pm EDT in New York City ... team will present an overview of the Company,s pipeline ... Phase 2b clinical trials for the treatment of patients ...
(Date:6/30/2015)... Fla. , June 30, 2015  July 4 th ... declaration of independence, and the spirit and people behind it. ... Foundation has partnered with USA Medical ... help increase funding for programs that empower independence for our ... country, and help more people afford their prescriptions. ...
(Date:6/30/2015)... WAYNE, Pa. , June 30, 2015 ... ("Egalet"), a fully integrated specialty pharmaceutical company ... pain treatments, today announced top-line results from ... study of Egalet-002, an abuse-deterrent, extended-release, oral ... for the management of pain severe enough ...
Breaking Medicine Technology:Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015 2Hope For Heroes and USA Medical Card Make a Difference for Our Nation's Heroes 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 3Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 4Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 5
... Targeting Pro-Inflammatory,Protein -, GAITHERSBURG, Md., April 18, ... publication of preclinical,study data demonstrating a role ... nuclear DNA-binding protein, in the pathology,of systemic ... or lupus) and rheumatoid arthritis. Data to ...
... RIDGE, N.J., April 19, 2007 /PRNewswire-FirstCall/ --,VioQuest ... focused on acquiring, developing and,commercializing targeted cancer ... VQD- 002, a direct inhibitor of Akt,activation ... tumors.,Pre-clinical data was presented in a poster ...
Cached Medicine Technology:MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases 2MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 2VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 4VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 5
(Date:6/30/2015)... ... 2015 , ... Carey Danis & Lowe comments on a new ... Virginia federal court. The court document outlined the judge’s plan to consolidate 26 vaginal ... Carey Danis & Lowe is a personal injury law firm with headquarters in St. ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... Ticket Down is a reputable source of ... native of Detroit, MI, Kid Rock, is hitting the road again this summer in what ... and hip hop superstar kicked off his summer tour this year at the XFINITY Theatre ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... Texas have launched a ‘responsive design’ website to inform potential sinus surgery patients ... them. , The website includes information about a wide variety of ENT issues ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... pleased to announce it’s own Debby Mann, CPC, RCC, ROCC, Coding Documentation and ... Summit with the Special Recognition Award for her contribution to the RBMA Coding ...
(Date:6/30/2015)... ... June 30, 2015 , ... Today, Grand ... “Grand Terrace Health Care Center.” Each year, Medicare ranks care centers around the ... best facility for their needs. Grand Terrace prides itself on quality in each ...
Breaking Medicine News(10 mins):Health News:Carey Danis & Lowe Comments on New Pretrial Order in Vaginal Mesh Lawsuit 2Health News:Carey Danis & Lowe Comments on New Pretrial Order in Vaginal Mesh Lawsuit 3Health News:Cheap Kid Rock Tickets at the DTE Energy Music Theatre in Clarkston: Ticket Down Has Slashed Prices On All Kid Rock Tickets at DTE in the Detroit Metro Area 2Health News:Clear Lake Medical Center ENT Launches ‘Responsive Design’ Website 2Health News:Clear Lake Medical Center ENT Launches ‘Responsive Design’ Website 3Health News:ADVOCATE’s Debby Mann Honored With Special Recognition Award 2Health News:Grand Terrace Health Care Center Announces Five-Star Rating in YouTube Video 2
... of Pennsylvania School of Medicine have created the first ... a mutation known to produce disease in people, an ... in the October issue of Human Molecular Genetics. ... of vision loss in elderly people, affecting more than ...
... Oct. 9 The following was released,today by the ... MR. TENPAS: Good morning. I am Ronald ... Natural Resources Division here at the,Department of Justice. ... administrator for Enforcement and Compliance Assurance., We ...
... wane over time, study finds , , TUESDAY, Oct. 9 ... who,ve lost weight keep it off, new research suggests. ... of the maintenance programs wears off over time, suggesting ... maintain healthier lifestyles. , "We were excited ...
... a potentially novel way to fight colorectal cancer using ... cancer cells, unlike current treatments that bind to the ... cause unwanted side effects. , In laboratory studies ... system proved able to specifically target colon cancer cells, ...
... NEW YORK, Oct. 9 Highlands Acquisition Corp.,(Amex: HIA.U), ... public offering (the "IPO") of 12,000,000 units. Each unit ... which entitles the holder to,purchase one share of common ... $10.00 per unit, generating gross proceeds of $120,000,000 to ...
... age of 12 currently drink alcohol, according to a ... Services Administration. While the majority of people who drink ... in the expression of violence. , By far the ... violent behavior involves alcohol, says Dr. Jeff Kretschmar, a ...
Cached Medicine News:Health News:Model to study age-related macular degeneration could pave way for better treatment 2Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 2Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 3Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 4Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 5Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 6Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 7Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 8Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 9Health News:Maintenance Treatment Helps Kids Keep Weight Off 2Health News:Maintenance Treatment Helps Kids Keep Weight Off 3Health News:Maintenance Treatment Helps Kids Keep Weight Off 4Health News:Inside job: new radioactive agents for colon cancer work inside cells 2Health News:Highlands Acquisition Corp. Completes Initial Public Offering 2Health News:Highlands Acquisition Corp. Completes Initial Public Offering 3
The CKMB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase MB isoenzyme activity in serum and plasma...
For the quantitative in vitro determination of Cholesterol in serum and plasma....
The ALP method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of alkaline phosphatase activity in serum or plasma....
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
Medicine Products: